John Trizzino, Novavax Executive Vice President, Chief Business Officer and Chief Financial Officer Joins BioTalk to Discuss the Company’s History, COVID-19 Vaccine Development, and Collaboration in the BioHealth Capital Region
Listen now on Apple https://apple.co/2EJ4ucS, Google https://bit.ly/36eBQLS, Spotify, https://spoti.fi/2HDE9hr, TuneIn https://bit.ly/3kS20Z1, and Youtube (audio) https://bit.ly/3kYlHyb.
Mr. Trizzino is executive vice president, chief business officer, and chief financial officer with responsibility for all pre-commercial and commercial launch strategy and execution, financial reporting, corporate funding, and investor/public relations. He previously served as senior vice president of commercial operations beginning in 2014. Mr. Trizzino originally joined Novavax in 2009 with a broad range of experiences in small-to-large, publicly held companies. He has an extensive background in the vaccine market with previous roles overseeing commercialization, vaccine policy, strategic development, business development, financing, investor relations, and public relations. In 2011, Mr. Trizzino joined Immunovaccine as its CEO and successfully led the company into clinical development of its lead candidate while securing the required funding commitments in the equity market as well as non-dilutive sources. Prior to his tenures at Novavax and Immunovaccine, Mr. Trizzino had leadership responsibilities at MedImmune, LLC (an AstraZeneca company), ID Biomedical, and Henry Schein, Inc., which were all companies focused on infectious disease vaccine markets. Mr. Trizzino received a bachelor of science degree from Long Island University, CW Post and a master of business administration degree from New York University, Stern School of Business.
Click here to download the transcript.